← Russell 3000 cross-section

BDX BECTON DICKINSON & CO

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$51.7bn
Revenue TTM
$20.8bn
Net income TTM
$941m
Free cash flow
$2.7bn
Composite score
45.0
Sector rank
#231

Valuation

P / E
55.0
EV / EBITDA
15.5
EV / sales
3.3
FCF yield
5.28%
Earnings yield vs 10-yr
-2.91pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
4.5%
EBITDA margin
21.0%
ROE
3.9%
ROIC
5.0%
Revenue growth
-2.5%

Insider activity, last 90 days

Net open-market
$-1.99m
Buyers
0
Sellers
4

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

We continue to invest in research and development, strategic tuck-in acquisitions, geographic expansion, and new product programs to drive further revenue and profit growth. Overview of Financial Results and Financial Condition For the three months ended June 30, 2026, worldwide revenues of $4.983 billion increased 5.4% from the prior-year period. This increase reflected the following impacts: (a) Volume/other includes revenues attributable to products and services. Growth within the Medication Management Solutions unit was partially offset by an unfavorable comparison to stronger sales of Alaris systems in the prior-year period that were driven by U.S. return-to-market efforts. …BECTON DICKINSON & CO, 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →